Navigation Links
Pancreas-targeted siRNA In Vivo Transfection Kit from Altogen Biosystems
Date:3/6/2012

LAS VEGAS, March 6, 2012 /PRNewswire/ -- Altogen Biosystems announced the launch of its new pancreas-targeted in vivo RNAi transfection system in the company's popular in vivo delivery product line for use in laboratories and research facilities for development of new medicines and testing in cells and animals. This in vivo reagent is designed for targeted siRNA delivery into pancreas, however it is also compatible for transfection of any negatively charged molecules including RNA, DNA, proteins, and small molecules.

The pancreas is very important hormone-secreting organ in the human body. Pancreatic diseases include: Diabetes, pancreatitis, cystic fibrosis, and neoplasms. Pancreatic cancer is the fourth leading cause of cancer death in the United States with a lowest survival rate of its victims than any other form of cancer. Researchers in diabetes, pancreatic cancer, and other pancreas disorders, are focused on discovering and developing new therapeutics for patients. Testing novel compounds require efficient and targeted delivery of pharmaceuticals into pancreas tissue (known as in vivo transfection).

Pancreas-targeted siRNA In Vivo Transfection Kit enables researchers to utilize in vivo transfection method to introduce DNA, RNA, and other molecules into pancreas cells. This liposome-based technology makes it possible to cross the cellular barriers and deliver genetic material, or a small interfering RNA (siRNA) into the cells for research or therapeutic purposes.  Highly efficient targeted delivery of biomolecules to pancreas tissue is achieved via multiple administration routes: intravenous, intratumoral, intraperitoneal, or subcutaneous.

About Altogen Biosystems

Altogen Biosystems (www.altogen.com) is a life sciences company located in Las Vegas, Nevada. Altogen Biosystems specializing in the development of pre-optimized in vitro transfection reagents and in vivo delivery systems, transfection products and services. Altogen Labs (www.altogenlabs.com) is a GLP-compliant laboratory contract research organization.  The company offers pre-clinical research and biology CRO services including: xenograft animal models (cancer), cryopreservation and cell banking services, generation of stable cell lines, gene silencing RNAi services, tissue-targeted in vivo siRNA and DNA delivery services, custom liposome encapsulation, and cell-based assay development. 

Link: Pancreas-targeted siRNA In Vivo Transfection Kit  - http://www.altogen.com/Pancreas-In-Vivo-Transfection-Reagent-mouse-rat-tumor-animal-model-sirna-dna-protein-pancreas-invivo-delivery.php


'/>"/>
SOURCE Altogen Biosystems
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Silence Therapeutics Signs siRNA Delivery Collaboration With Top 10 Pharma Company
2. Silence Therapeutics Receives Notice of Allowance for New U.S. Patent Covering Novel Small Interfering RNA (siRNA) Delivery Technology
3. Sirnaomics Seals a Second Partnership Deal with a Chinese Pharmaceutical Company for Developing siRNA Therapeutics
4. Quark Pharmaceuticals Doses First Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Patient in Stratum II of its Clinical Study of siRNA Drug Candidate QPI-1007
5. Silence Therapeutics Issued New Patents Covering siRNA Sequences for RNA Interference Therapeutics
6. Quark Pharmaceuticals and Major Pharmaceutical Company Enter into Licensing Option Agreement for the p53 Suppressor Drug QPI-1002, the First siRNA Administered Systemically in Human
7. Silence Therapeutics and AstraZeneca Extend siRNA Development Collaboration
8. Quark Reports Progress of siRNA Clinical Programs; 300 Patients Dosed With Quark Pharmaceuticals siRNA Drugs In Multiple Fully Enrolled Clinical Trials
9. Quark Pharmaceuticals to Present Data on its siRNA Therapeutic Programs in Kidney and Lung Diseases
10. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
11. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... April 20, 2017  Zimmer Biomet Holdings, Inc. (NYSE ... today announced that it will be participating in the ... the InterContinental Hotel in Boston, Massachusetts ... present at 11:20 a.m. Eastern Time. A ... Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com .  ...
(Date:4/20/2017)... DUBLIN , April 20, 2017 Research ... Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market and ... to their offering. ... market for drug delivery technologies will rise from USD 20 Billion ... Global Drug Delivery Technologies - Innovation Driven by Rapidly ...
(Date:4/20/2017)...  AbbVie (NYSE: ABBV), a global biopharmaceutical company, ... hepatitis C virus (HCV) infected patients with genotype ... cirrhosis (Child-Pugh A) achieved sustained virologic response at ... investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high ... weeks of G/P treatment without ribavirin. Patients with ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America ... lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start ... ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... The Texas ... in recently to the labor and delivery team at Women’s Hospital at Renaissance in ... who give birth at the hospital and decide to donate. , “Women’s Hospital ...
(Date:4/28/2017)... ... ... Bill Howe started his sewer and drain company in 1980 focusing heavily ... team, the Bill Howe brand was born and they began cultivating their mission to ... the San Diego community in which they worked, lived and were raising their daughters. ...
(Date:4/28/2017)... ... , ... Intellitec Solutions announced the publication of a case ... GP solution that integrates to their PointClickCare EHR software package. With the guidance ... Grove now has the capability to achieve its goal for a comprehensive EHR ...
(Date:4/28/2017)... ... April 28, 2017 , ... Semrock’s ... is the premier online modeling resource for fluorescence microscopists and optical system designers, ... during last 5 years spanning the globe, SearchLight has become a tremendously popular ...
Breaking Medicine News(10 mins):